ʻO ka hoʻāʻo hou no ka mālama ʻana i ka Melanoma kiʻekiʻe

A HOLD Hoʻokuʻu ʻole 5 | eTurboNews | eTN
Avatar o Linda Hohnholz
i kakauia ma Linda Hohnholz

Ua hoʻolaha ʻo Phio Pharmaceuticals Corp. i kēia lā ua wehe ʻo ia i ke kākau inoa ʻana i nā mea maʻi i ka Phase 1b clinical trial o PH-762 no ka mālama ʻana i ka melanoma kiʻekiʻe.

"ʻOliʻoli mākou i ka holomua ʻana i kā mākou hoʻokolohua lapaʻau mua i loko o ke kanaka no kā mākou papahana alakaʻi, PH-762, e mālama i nā maʻi me ka melanoma. ʻO ka hoʻomaka ʻana o kēia haʻawina hoʻomaʻamaʻa e hōʻailona i kahi mea nui no Phio a me kā mākou INTASYL therapeutic platform, "wahi a Kauka Gerrit Dispersyn, Pelekikena a Luna Nui o Phio. "He haʻawina koʻikoʻi kēia no nā poʻe maʻi me ka melanoma holomua, ʻoiai i kēia manawa, ʻaʻohe koho lapaʻau neoadjuvant i ʻae ʻia no kēia mau maʻi. Eia kekahi, kākoʻo ʻia ka papahana lapaʻau no PH-762 e mālama i ka melanoma e kahi pūʻulu ikaika o ka ʻikepili preclinical i hana ʻia i nā makahiki i hala. Hōʻike kēia mau ʻikepili i ka mālama ʻana i ka PH-762 ʻaʻole wale i ka ulu ʻana o ka maʻi maʻi kūloko, akā hoʻopuka pū kekahi i kahi hopena abscopal a i ʻole ka pane ʻana o ka immune systemic i nā maʻi maʻi distal, untreated.

ʻO ke aʻo ʻana o ka Phase 1b, e mālama ʻia ana ma ka Gustave Roussy Institute, kekahi o nā kikowaena maʻi maʻi nui loa ma ʻEulopa, e loiloi i ka palekana, tolerability, pharmacokinetics a me ka hana anti-tumor o PH-762 i kahi neoadjuvant hoʻonohonoho i nā kumuhana me ka melanoma kiʻekiʻe. . E hōʻike ana ke aʻo ʻana i ke kauka i ka piʻi ʻana o ka nui o ka PH-762 monotherapy a ua hoʻolālā ʻia e ʻae i kahi loiloi i alakaʻi ʻia i ka ʻikepili o ka Phase 2 i manaʻo ʻia. ʻO kēia ka hoʻokolohua lapaʻau mua me PH-762.

ʻO PH-762, hoʻāla i nā cell immune e ʻike maikaʻi a pepehi i nā maʻi maʻi maʻi. Hana ia ma ka hōʻemi ʻana i ka ʻōlelo o PD-1, kahi pahuhopu i hoʻopaʻa ʻia i ke kino no ka immunotherapy. Hōʻike ʻia ka PD-1 e nā pūnae T a pale iā lākou mai ka pepehi ʻana i nā maʻi maʻi maʻi. Ke hōʻemi ʻo PH-762 i ka hōʻike PD-1, hoʻokuʻu ʻia nā "brakes" ma ka ʻōnaehana pale a hoʻāla i nā pūnae T e pepehi i nā pūnaʻi kanesa. Hoʻomohala ʻia ʻo PH-762 ma ke ʻano he lāʻau lapaʻau kūʻokoʻa me ka hoʻokele kūloko i kahi ʻōpū. Eia kekahi, ua hoʻomohala ʻia ʻo ia ma ke ʻano he mea koʻikoʻi o ka immunotherapy cellular, ʻoi aku ka nui o ka hoʻomaikaʻi ʻana i ka hiki ke pepehi i ka cell tumor o ka hoʻoneʻe ʻana i ka tumor infiltrating lymphocyte (TIL) therapy.

No ka mea kākau

Avatar o Linda Hohnholz

Linda Hohnholz

Lunahooponopono no eTurboNews ma ka eTN HQ.

kakau
E hoʻomaopopo i
malihini
0 Comments
Nā ʻōlelo Hoʻohui Kūʻai
E nānā i nā ʻōlelo āpau
0
E aloha nui i kou mau manaʻo, e ʻoluʻolu.x
()
x
Kaʻana like i...